- Home
- DVA vs EXEL Comparison
DVA vs EXEL Comparison
Compare DVA & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVA
- EXEL
- Stock Information
- Founded
- DVA 1994
- EXEL 1994
- Country
- DVA United States
- EXEL United States
- Employees
- DVA N/A
- EXEL N/A
- Industry
- DVA Misc Health and Biotechnology Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DVA Health Care
- EXEL Health Care
- Exchange
- DVA Nasdaq
- EXEL Nasdaq
- Market Cap
- DVA 10.8B
- EXEL 12.0B
- IPO Year
- DVA 1995
- EXEL 2000
- Fundamental
- Price
- DVA $146.06
- EXEL $44.35
- Analyst Decision
- DVA Hold
- EXEL Buy
- Analyst Count
- DVA 4
- EXEL 18
- Target Price
- DVA $157.00
- EXEL $44.29
- AVG Volume (30 Days)
- DVA 752.6K
- EXEL 3.0M
- Earning Date
- DVA 08-05-2025
- EXEL 07-28-2025
- Dividend Yield
- DVA N/A
- EXEL N/A
- EPS Growth
- DVA 14.90
- EXEL 237.58
- EPS
- DVA 10.11
- EXEL 2.20
- Revenue
- DVA $12,968,524,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- DVA $6.51
- EXEL $9.93
- Revenue Next Year
- DVA $3.41
- EXEL $13.17
- P/E Ratio
- DVA $14.44
- EXEL $20.18
- Revenue Growth
- DVA 5.11
- EXEL 24.49
- 52 Week Low
- DVA $131.76
- EXEL $22.20
- 52 Week High
- DVA $179.60
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- DVA 56.00
- EXEL 51.18
- Support Level
- DVA $138.65
- EXEL $44.07
- Resistance Level
- DVA $144.07
- EXEL $45.52
- Average True Range (ATR)
- DVA 3.16
- EXEL 1.39
- MACD
- DVA -0.09
- EXEL -0.15
- Stochastic Oscillator
- DVA 75.61
- EXEL 14.74
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.